Free Trial

Sanofi (SNY) Competitors

Sanofi logo
$50.24 +0.11 (+0.21%)
As of 03:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SNY vs. NVO, NVS, AZN, GSK, TAK, ARGX, ONC, BNTX, SMMT, and INSM

Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Novo Nordisk A/S (NVO), Novartis (NVS), AstraZeneca (AZN), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

Sanofi vs. Its Competitors

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$42.12B7.60$14.64B$3.3821.22
Sanofi$44.46B2.77$6.02B$2.8017.91

Novo Nordisk A/S has a net margin of 34.52% compared to Sanofi's net margin of 14.56%. Novo Nordisk A/S's return on equity of 80.94% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Nordisk A/S34.52% 80.94% 24.23%
Sanofi 14.56%17.15%9.80%

Novo Nordisk A/S has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Novo Nordisk A/S pays an annual dividend of $1.64 per share and has a dividend yield of 2.3%. Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.2%. Novo Nordisk A/S pays out 48.5% of its earnings in the form of a dividend. Sanofi pays out 57.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Sanofi. MarketBeat recorded 43 mentions for Novo Nordisk A/S and 22 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 1.19 beat Sanofi's score of 0.98 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novo Nordisk A/S
33 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive
Sanofi
12 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Novo Nordisk A/S presently has a consensus price target of $112.00, indicating a potential upside of 56.18%. Sanofi has a consensus price target of $61.50, indicating a potential upside of 22.61%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S
2 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.27
Sanofi
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.11

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.

Get Sanofi News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNY vs. The Competition

MetricSanofiLarge Cap Pharma IndustryMedical SectorNASDAQ Exchange
Market Cap$122.91B$258.98B$5.72B$9.52B
Dividend Yield3.19%2.82%4.60%3.99%
P/E Ratio17.9027.9528.0720.02
Price / Sales2.775.05462.58104.32
Price / Cash9.4114.1136.5558.97
Price / Book1.5117.988.645.90
Net Income$6.02B$8.49B$3.24B$258.50M
7 Day Performance3.81%3.43%4.08%2.12%
1 Month Performance4.94%3.42%10.68%12.62%
1 Year Performance-5.54%-5.93%34.47%19.25%

Sanofi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNY
Sanofi
3.5194 of 5 stars
$50.24
+0.2%
$61.50
+22.4%
-2.1%$123.24B$44.46B17.9582,878Upcoming Earnings
NVO
Novo Nordisk A/S
4.2334 of 5 stars
$64.96
+1.0%
$112.00
+72.4%
-46.2%$290.05B$42.12B19.2277,349Positive News
NVS
Novartis
1.5831 of 5 stars
$114.18
-0.1%
$123.67
+8.3%
+7.4%$241.20B$50.32B16.6275,883Positive News
AZN
AstraZeneca
2.9476 of 5 stars
$68.72
-0.1%
$89.00
+29.5%
-7.6%$213.12B$54.07B27.6094,300Upcoming Earnings
GSK
GSK
1.7302 of 5 stars
$36.21
-0.3%
$37.38
+3.2%
-2.8%$74.12B$40.10B18.6668,629Upcoming Earnings
Analyst Revision
TAK
Takeda Pharmaceutical
1.6965 of 5 stars
$14.46
+0.2%
N/A+8.0%$45.99B$30.09B65.7147,455Upcoming Earnings
High Trading Volume
ARGX
argenex
3.6803 of 5 stars
$566.14
+0.3%
$728.06
+28.6%
+27.4%$34.65B$2.25B34.931,599Upcoming Earnings
Analyst Revision
ONC
BeOne Medicines
1.2888 of 5 stars
$291.93
-0.9%
$327.56
+12.2%
N/A$32.00B$3.81B-78.4811,000Insider Trade
Gap Down
BNTX
BioNTech
1.4251 of 5 stars
$108.91
-1.0%
$136.58
+25.4%
+37.8%$26.18B$2.98B-32.036,772News Coverage
SMMT
Summit Therapeutics
2.1494 of 5 stars
$26.34
+0.5%
$34.67
+31.6%
+176.3%$19.56B$700K-77.47110Positive News
INSM
Insmed
3.9455 of 5 stars
$102.78
+0.2%
$108.47
+5.5%
+39.1%$19.50B$363.71M-17.271,271Positive News
Analyst Forecast
Insider Trade

Related Companies and Tools


This page (NASDAQ:SNY) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners